A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

BACKGROUND: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when given as combination therapy. METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustin, G J, Shreeves, G, Nathan, P D, Gaya, A, Ganesan, T S, Wang, D, Boxall, J, Poupard, L, Chaplin, D J, Stratford, M R L, Balkissoon, J, Zweifel, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865759/
https://www.ncbi.nlm.nih.gov/pubmed/20389300
http://dx.doi.org/10.1038/sj.bjc.6605650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865759/
https://www.ncbi.nlm.nih.gov/pubmed/20389300
http://dx.doi.org/10.1038/sj.bjc.6605650

Ejemplares similares